Recommendations on screening for colorectal cancer in primary care

CMAJ

Volumn 188, Issue 5, 2016, Pages 340-348

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; FECES ANALYSIS; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; SCREENING TEST; SIGMOIDOSCOPY; AGED; CANADA; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANADA; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; PRIMARY HEALTH CARE; SIGMOIDOSCOPY;

EID: 84960870733     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.151125     Document Type: Article

References (44)

1. Canadian Cancer Society?s Advisory Committee on Cancer Sta-Tistics. Canadian cancer statistics 2015. Toronto: Canadian Can-cer Society; 2015. Available: www.cancer.ca/~/media/cancer. ca/CW /cancer%20information/cancer%20101/Canadian%20 cancer %20statistics/Canadian-Cancer-Statistics-2015-EN.pdf (accessed 2015 Aug. 31
2. Canadian Cancer Society?s Advisory Committee on Cancer Sta-Tistics. Canadian cancer statistics 2014. Toronto: Canadian Can-cer Society; 2014. Available: www.cancer.ca/~/media/cancer.ca/.CW/cancer%20information/cancer%20101/Canadian%20 cancer %20statistics/Canadian-Cancer-Statistics-2014-EN.pdf (accessed 2015 Mar. 31
3. Colorectal Cancer Network (CRCNet) comprehensive report. Toronto: Cancer Care Ontario; 2011.
4. Age and sex highlight tables, 2011 census. Ottawa: Statistics Can-Ada; 2015. Available: www12.statcan.gc.ca/census-recensement /2011 /dp-pd/hlt-fst/as-sa/index-eng.cfm?Lang=E (accessed 2015 Aug. 18
5. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975; 36: 2251-70.
6. The 2014 cancer system performance report. Toronto: Canadian Partnership Against Cancer; 2014. Available: www.cancerview. ca/idc/groups/public/documents/webcontent/sp-report-2014.pdf (accessed 2015 Mar. 31
7. Canadian Task Force on Preventive Health Care. Colorectal can-cer screening: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2001; 165: 206-8.
8. McLeod R; Canadian Task Force on Preventive Health Care. Screening strategies for colorectal cancer: systematic review &recommendations. Can J Gastroenterol. 2001; 15: 647-60.
9. Schünemann H, Brozek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Ver-sion 3.2 [updated March 2009]. The GRADE Working Group; 2009.
10. Connor Gorber S, Singh H, Pottie K, et al. Process for guideline development by the reconstituted Canadian Task Force on Preven-Tive Health Care. CMAJ. 2012; 184: 1575-81.
11. Fitzpatrick-Lewis D, Usman A, Ciliska D, et al. Screening for colorectal cancer. Ottawa: Canadian Task Force on Preventive Health Care; 2015. Available: www.canadiantaskforce.ca/.ctf phc-guidelines/2015-colorectal-cancer/systematic-review (accessed 2016 Feb. 11
12. Kronborg O, Jorgensen OD, Fenger C, et al. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004; 39: 846-51.
13. Lindholm E, Brevinge H, Haglind E. Survival benefit in a ran-domized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. 2008; 95: 1029-36.
14. Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012; 61: 1036-40.
15. Shaukat A, Mongin SJ, Geisser MS, et al. Long-Term mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-14.
16. Zheng S, Chen K, Liu X, et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum. 2003; 46: 51-8.
17. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375: 1624-1633.
18. Hoff G, Grotmol T, Skovlund E, et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ. 2009; 338(b1846
19. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366: 2345-57.
20. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidos-copy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst. 2011; 103: 1310-22.
21. Newcomb PA, Storer BE, Morimoto LM, et al. Long-Term effi-cacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst. 2003; 95: 622-5.
22. Rabeneck L, Rumble RB, Thompson F, et al.; FIT Guidelines Expert Panel. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012; 26: 131-47.
23. van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immuno-chemical faecal occult blood test in a colorectal cancer screen-ing programme. Br J Cancer. 2009; 101: 1274-81.
24. Hol L, Wilschut JA, Van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immuno-chemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009; 100: 1103-10.
25. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on perfor-mance characteristics. J Natl Cancer Inst. 2007; 99: 1462-70.
26. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screen-ing. Am J Gastroenterol. 2010; 105: 2017-25.
27. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Pre-ventive Services Task Force. Ann Intern Med. 2008; 149: 638-58.
28. Lin JS, Piper MA, Perdue LA, et al. Draft evidence review. Colorectal cancer: screening. Rockville (MD): US Preventive Ser-vices Task Force; [updated 2015]. Available: www.us preventive servicestaskforce.org/Page/Document/draft-evidence-review54/.colorectal-cancer-screening2 (accessed 2015 Dec. 14
29. Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoid-oscopy and colorectal cancer mortality. J Natl Cancer Inst. 1992; 84: 1572-5.
30. Selby JV, Friedman GD, Quesenberry CP Jr, et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992; 326: 653-7.
31. Leddin D, Armstrong D, Borgaonkar M, et al. The 2012 SAGE wait times program: survey of access to gastroenterology in Canada. Can J Gastroenterol. 2013; 27: 83-9.
32. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 370: 1287-97.
33. Colorectal cancer screening guidelines across Canada: environ-mental scan. Toronto: Canadian Partnership Against Cancer; 2015. Available: www.cancerview.ca/cv/portal/Home/.Prevention And Screening/PSProfessionals/PSScreening AndEarly Diagnosis /.ColorectalCancerScreeningPage?-afrLoop=8588379565163000&l ang=en&afrWindowMode=0&adf.ctrl-state=1cklla0r0d-172 (accessed 2016 Feb. 10
34. Toward Optimized Practice (TOP) Working Group for Colorectal Cancer Screening. Colorectal cancer screening: clinical practice guideline. Edmonton: Toward Optimized Practice; [updated 2013]. Available: www.topalbertadoctors.org/download/1009/colorectal-guideline.pdf?-20150307043502 (accessed 2015 Aug. 15
35. Registered nurse flexible sigmoidoscopy. Toronto: Cancer Care Ontario; 2015. Available: www.cancercare .on.ca/pcs/screening/coloscreening/rnfs (accessed 2015 Aug. 31
36. Bowel cancer screening: programme overview. London (UK): Public Health England; [updated 2015]. Available: www.gov.uk/guidance/bowel-cancer-screening-programme-overview (accessed 2015 Dec. 14
37. Bowel cancer screening. London (UK): National Health Service; [updated 2015]. Available: www.nhs. uk/conditions/bowel-cancer-screening/pages/bowel-scope-screening.aspx (accessed 2015 Dec. 14
38. Marshall DA, Johnson FR, Phillips KA, et al. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007; 10: 415-30.
39. Dolan JG, Boohaker E, Allison J, et al. Patients? preferences and priorities regarding colorectal can-cer screening. Med Decis Making. 2013; 33: 59-70 .
40. Telford JJ, Levy AR, Sambrook JC, et al. The cost-effectiveness of screening for colorectal cancer. CMAJ. 2010; 182: 1307-13.
41. Heitman SJ, Hilsden RJ, Au F, et al. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med. 2010; 7: e1000370.
42. Cancer risk management model. Toronto: Canadian Partnership Against Cancer; [updated 2015]. Available: www.cancerview.ca/cancerriskmanagement (accessed 2015 June 1
43. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 627-37.
44. Colorectal cancer: screening. Rockville (MD): US Preventive Services Task Force. Available: www. uspreventiveservices taskforce.org/uspstf/uspscolo.htm (accessed 2015 May 13